1. Home
  2. CCCC vs SNCR Comparison

CCCC vs SNCR Comparison

Compare CCCC & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCCC
  • SNCR
  • Stock Information
  • Founded
  • CCCC 2015
  • SNCR 2000
  • Country
  • CCCC United States
  • SNCR United States
  • Employees
  • CCCC N/A
  • SNCR N/A
  • Industry
  • CCCC Biotechnology: Pharmaceutical Preparations
  • SNCR EDP Services
  • Sector
  • CCCC Health Care
  • SNCR Technology
  • Exchange
  • CCCC Nasdaq
  • SNCR Nasdaq
  • Market Cap
  • CCCC 115.0M
  • SNCR 101.2M
  • IPO Year
  • CCCC 2020
  • SNCR 2006
  • Fundamental
  • Price
  • CCCC $1.50
  • SNCR $7.44
  • Analyst Decision
  • CCCC Buy
  • SNCR Strong Buy
  • Analyst Count
  • CCCC 4
  • SNCR 1
  • Target Price
  • CCCC $12.50
  • SNCR $13.00
  • AVG Volume (30 Days)
  • CCCC 1.3M
  • SNCR 96.2K
  • Earning Date
  • CCCC 05-07-2025
  • SNCR 05-06-2025
  • Dividend Yield
  • CCCC N/A
  • SNCR N/A
  • EPS Growth
  • CCCC N/A
  • SNCR N/A
  • EPS
  • CCCC N/A
  • SNCR N/A
  • Revenue
  • CCCC $39,783,000.00
  • SNCR $172,842,000.00
  • Revenue This Year
  • CCCC N/A
  • SNCR $2.59
  • Revenue Next Year
  • CCCC $36.31
  • SNCR $4.91
  • P/E Ratio
  • CCCC N/A
  • SNCR N/A
  • Revenue Growth
  • CCCC 98.56
  • SNCR 4.64
  • 52 Week Low
  • CCCC $1.09
  • SNCR $7.13
  • 52 Week High
  • CCCC $7.66
  • SNCR $15.46
  • Technical
  • Relative Strength Index (RSI)
  • CCCC 46.32
  • SNCR 32.03
  • Support Level
  • CCCC $1.42
  • SNCR $7.69
  • Resistance Level
  • CCCC $1.64
  • SNCR $8.84
  • Average True Range (ATR)
  • CCCC 0.15
  • SNCR 0.79
  • MACD
  • CCCC 0.02
  • SNCR -0.32
  • Stochastic Oscillator
  • CCCC 25.64
  • SNCR 2.93

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a leading provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and highly scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

Share on Social Networks: